[PMID]: | 28637435 |
[Au] Autor: | Zhou YL; Chen CL; Wang YX; Tong Y; Fang XL; Li L; Wang ZY |
[Ad] Endereço: | Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China. |
[Ti] Título: | Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis. |
[So] Source: | BMC Ophthalmol;17(1):97, 2017 Jun 21. |
[Is] ISSN: | 1471-2415 |
[Cp] País de publicação: | England |
[La] Idioma: | eng |
[Ab] Resumo: | BACKGROUND: Anti-angiogenesis treatments are the most commonly used treatments for the vision loss caused by exudative age-related macular degeneration (AMD), in which the anti-vascular endothelial growth factor (VEGF) drugs with ranibizumab and bevacizumab are current standard treatments. However, the outcome of anti-VEGF therapeutics is not uniform in all patients. METHODS: We performed a literature-based meta-analysis including, five published studies relevant to HTRA1 and response to anti-VEGF treatment (bevacizumab or ranibizumab). Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Sensitivity analysis and meta-regression were also performed. Q-statistic test and Egger's test was used to evaluate heterogeneity and publication bias respectively. RESULTS: Overall, no association between the rs11200638 polymorphism in HTRA1 gene and the anti-VEGF treatment response was found in the genotype GG versus AA (OR = 1.06; 95% CI: 0.77 to 1.48; P = 0.98), genotype GA versus AA (OR = 1.11; 95% CI: 0.83 to 1.47; P = 0.93), genotype GG + GA versus AA (OR = 1.22; 95% CI: 0.94 to 1.57; P = 0.09), and allele G versus A (OR = 0.92; 95% CI: 0.78 to 1.08; P = 0.14). In the subgroup analysis by ethnicity Caucasian population, and a significant association was still not observed in all genetic models. Sensitivity analysis indicated the robustness of our findings, and no publication bias was observed in our meta-analysis. CONCLUSIONS: This study shows that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD. However, more studies are needed to further prove the conclusion of present study, especially well-designed and high quality randomised controlled trials or intervention studies. |
[Mh] Termos MeSH primário: |
Inibidores da Angiogênese/uso terapêutico DNA/genética Predisposição Genética para Doença Polimorfismo de Nucleotídeo Único Serina Endopeptidases/genética Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores Degeneração Macular Exsudativa
|
[Mh] Termos MeSH secundário: |
Alelos Genótipo Serina Peptidase 1 de Requerimento de Alta Temperatura A Seres Humanos Serina Endopeptidases/metabolismo Degeneração Macular Exsudativa/tratamento farmacológico Degeneração Macular Exsudativa/genética Degeneração Macular Exsudativa/metabolismo
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; META-ANALYSIS; REVIEW |
[Nm] Nome de substância:
| 0 (Angiogenesis Inhibitors); 0 (Vascular Endothelial Growth Factor A); 9007-49-2 (DNA); EC 3.4.21.- (High-Temperature Requirement A Serine Peptidase 1); EC 3.4.21.- (HtrA1 protein, human); EC 3.4.21.- (Serine Endopeptidases) |
[Em] Mês de entrada: | 1710 |
[Cu] Atualização por classe: | 171116 |
[Lr] Data última revisão:
| 171116 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170623 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1186/s12886-017-0487-2 |
|
|